Adragos Pharma, a contract development & manufacturing organization (CDMO), has enhanced its production capabilities with the completion of a new ampoule filling line at its Livron-sur-Drôme site in France.
 
Adragos invested €13 million ($13.8 million) to boost the facility’s output by 30%, enabling the company to manufacture over 160 million ampoules annually and meet the growing demand in global pharmaceutical markets for sterile injectables.
 
The newly installed line, now the fourth at the facility, offers flexible fill volumes ranging from 1ml to 20ml, accommodating a wide variety of formulations and customer-specific needs.
 
The line allows aseptic fill and finish in accordance with the Annex 1 of the EU GMP regulations. This added versatility enables Adragos Pharma to uphold its rigorous quality and regulatory standards while delivering tailored solutions to clients.
 
The expansion not only increases production capacity but also strengthens the company’s operational efficiency. By modernizing its infrastructure, Adragos Pharma has enhanced its ability to swiftly adapt to market needs, further reinforcing its reputation as a reliable partner for pharmaceutical clients worldwide.
 
The expansion also includes a new state-of-the-art cleanroom to drive efficiency and innovation.
  
This upgrade strengthens Adragos Pharma’s commitment to advancing its manufacturing capabilities and maintaining industry-leading standards.
 
Marco Gorgas, Adragos Pharma’s Chief Operating Officer, said: “The new line not only addresses regulatory and capacity demands but also supports our commitment to advancing patient care by meeting the evolving needs of our clients.”

Related Insights